Olodaterol Hydrochloride Patent Expiration
Olodaterol Hydrochloride is Used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Olodaterol Hydrochloride Patents
Given below is the list of patents protecting Olodaterol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Striverdi Respimat | US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism | Oct 16, 2030 | Boehringer Ingelheim |
Striverdi Respimat | US7837235 | Device for clamping a fluidic component | Mar 13, 2028 | Boehringer Ingelheim |
Striverdi Respimat | US9027967 | Device for clamping a fluidic component | Mar 31, 2027 | Boehringer Ingelheim |
Striverdi Respimat | US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease | Jan 19, 2027 | Boehringer Ingelheim |
Striverdi Respimat | US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device | Oct 10, 2026 | Boehringer Ingelheim |
Striverdi Respimat | US7896264 | Microstructured high pressure nozzle with built-in filter function | May 26, 2025 | Boehringer Ingelheim |
Striverdi Respimat | US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | May 12, 2025 | Boehringer Ingelheim |
Striverdi Respimat | US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | May 12, 2025 | Boehringer Ingelheim |
Striverdi Respimat | US7284474 | Piston-pumping system having o-ring seal properties |
Aug 26, 2024
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec 07, 2023
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov 10, 2023
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov 10, 2023
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov 10, 2023
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7988001 | Container provided with a pressure equalization opening |
Aug 04, 2021
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6988496 | Cartridge for a liquid |
Feb 23, 2020
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7802568 | Cartridge for a liquid |
Feb 26, 2019
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6846413 | Microstructured filter |
Aug 28, 2018
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6977042 | Microstructured filter |
Aug 28, 2018
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6149054 | Mechanical counter for a metering apparatus |
Dec 19, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6453795 | Locking mechanism for a spring-actuated device |
Dec 05, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US5964416 | Device for producing high pressure in a fluid in miniature |
Oct 04, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6176442 | Device for mounting a component exposed to a pressurized fluid |
Oct 04, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US6726124 | Device for producing high pressure in a fluid in miniature |
Oct 04, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7104470 | Device for producing high pressure in a fluid in miniature |
Oct 04, 2016
(Expired) | Boehringer Ingelheim |
Striverdi Respimat | US7246615 | Atomising nozzle and filter and spray generating device |
May 31, 2016
(Expired) | Boehringer Ingelheim |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Olodaterol Hydrochloride's patents.
Latest Legal Activities on Olodaterol Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Olodaterol Hydrochloride.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 19 Apr, 2023 | US8044046 |
Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2023 | US8034809 |
Payment of Maintenance Fee, 12th Year, Large Entity | 23 Feb, 2022 | US7786111 |
Payment of Maintenance Fee, 12th Year, Large Entity | 24 Nov, 2021 | US7727984 |
Payment of Maintenance Fee, 12th Year, Large Entity | 11 Aug, 2020 | US7491719 |
Patent Term Extension Certificate Critical | 16 Dec, 2019 | US7727984 |
Payment of Maintenance Fee, 8th Year, Large Entity | 16 Apr, 2019 | US8044046 |
Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2019 | US8034809 |
Notice of Final Determination -Eligible | 02 Apr, 2019 | US7727984 |
Payment of Maintenance Fee, 12th Year, Large Entity | 14 Nov, 2018 | US7220742 |